2Bai X, Jiang Y. Key factors in mTOR regulation. Cell Mol Life Sci, 2010,67:239-253. 被引量：1
3Helliwell SB, Wagner P, Kunz J, et al. TOR1 and TOR2 are structurally and functionally similar but not identical phosphatidylinositol kinase homologues in yeast. Mol Biol Cell, 1994,5 : 105-118. 被引量：1
4Menon S, Manning BD. Common corruption of the mTOR signaling network in human tumors. Oncogene, 2008,27 Suppl 2: S43-51. 被引量：1
5Sparks CA, Guertin DA. Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy. Oneogene, 2010, 29: 3733-3744. 被引量：1
6Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer therapy. J Clin Onco|, 2009,27 : 2278-2287. 被引量：1
7Bjornsti MA, Houghton PJ. The TOR pathway:a target for cancer therapy. Nat Rev Cancer, 2004,4:335-348. 被引量：1
8Slattery ML, Herrick J, Lundgreen A, et al. Genetic variation in a metabolic signaling pathway and colon and rectal cancer risk: roTOR, PTEN, STK1, RPKAA1, PRKAG2, TSC1, TSC2, PI3K, and Aktl. Carcinogenesis, 2010,31 : 1604-1611. 被引量：1
9Pencreach E, Gu6rin E, Nicolet C, et al. Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia-inducible factor-lalpha axis. Clin Cancer Res, 2009, 15:1297-1307. 被引量：1
10Guba M, yon Breitenbuch P, Steinbauer M, ct al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med, 2002, 8:128-135. 被引量：1
